Drug Search Results
More Filters [+]

Gadoteridol

Alternative Names: gadoteridol, prohance, prohance multipack
Latest Update: 2024-02-05
Latest Update Note: Clinical Trial Update

Product Description

Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Gadoteridol)

Mechanisms of Action: Contrast Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Colombia | Croatia | Czech | Denmark | Estonia | Finland | France | Germany | Greece | Hungary | India | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Gadoteridol

Countries in Clinic: Argentina, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Japan, Korea, Poland, South Korea, Sweden, Taiwan, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Brain Diseases|Other|Spinal Cord Diseases|Spinal Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Quanti OBR

P3

Recruiting

Other

2024-10-31

66%

Quanti OBR

P3

Recruiting

Other

2024-10-31

66%

Quanti OBR

P3

Recruiting

Other

2024-10-31

66%

Quanti OBR

P3

Recruiting

Other

2024-10-31

66%

Quanti OBR

P3

Recruiting

Other

2024-10-31

66%

Quanti CNS

P3

Recruiting

Other

2024-10-31

66%

Quanti CNS

P3

Recruiting

Other

2024-10-31

66%

Quanti CNS

P3

Recruiting

Other

2024-10-31

66%

Quanti CNS

P3

Recruiting

Other

2024-10-31

66%

CTR20232191

P3

Recruiting

Brain Diseases|Spinal Cord Diseases|Spinal Diseases

None

CTR20232190

P3

Recruiting

Spinal Cord Diseases|Brain Diseases|Spinal Diseases

None

Recent News Events